US-IVD
cobas® KRAS Mutation Test
IVD
For in vitro diagnostic use.

Identifies mutations in codons 12, 13 and 61 of the KRAS gene
The cobas® KRAS Mutation Test offers broad mutation coverage of KRAS codons 12, 13 and 61 to identify colorectal cancer patients who are not likely to respond to anti-EGFR monoclonal antibody therapies.
Features and benefits
- The cobas® KRAS Mutation Test detects major mutations in codons 12, 13 and 61 from colorectal cancer patients
- In formalin-fixed, paraffin-embedded tissue (FFPET), the cobas® KRAS Mutation Test can detect <5% mutant sequence copies in a background of wild-type DNA
- Robust, reliable KRAS test results can be obtained from a single, 5µm FFPET section with >10% tumor content using the cobas® KRAS Mutation Test
- The test can be performed in <8 hours so results can be reported to the treating physician within a few days from laboratory receipt of specimen
- Liquid, ready-to-use reagents increase laboratory efficiency
- Automated result interpretation and test reporting provides consistent, objective and reproducible results from laboratory to laboratory
Registration status
Would you like to know more about the cobas® KRAS Mutation Test?
Please submit your information in the following form to be contacted by a Roche representative with more details.